These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33952674)

  • 1. iPSC-endothelial cell phenotypic drug screening and in silico analyses identify tyrphostin-AG1296 for pulmonary arterial hypertension.
    Gu M; Donato M; Guo M; Wary N; Miao Y; Mao S; Saito T; Otsuki S; Wang L; Harper RL; Sa S; Khatri P; Rabinovitch M
    Sci Transl Med; 2021 May; 13(592):. PubMed ID: 33952674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
    Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
    Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Bone Morphogenetic Protein Receptor Type 2 (
    Devendran A; Kar S; Bailey R; Trivieri MG
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.
    Nickel NP; Spiekerkoetter E; Gu M; Li CG; Li H; Kaschwich M; Diebold I; Hennigs JK; Kim KY; Miyagawa K; Wang L; Cao A; Sa S; Jiang X; Stockstill RW; Nicolls MR; Zamanian RT; Bland RD; Rabinovitch M
    Am J Respir Crit Care Med; 2015 Jun; 191(11):1273-86. PubMed ID: 25853696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
    Happé C; Kurakula K; Sun XQ; da Silva Goncalves Bos D; Rol N; Guignabert C; Tu L; Schalij I; Wiesmeijer KC; Tura-Ceide O; Vonk Noordegraaf A; de Man FS; Bogaard HJ; Goumans MJ
    Cells; 2020 Jun; 9(6):. PubMed ID: 32521690
    [No Abstract]   [Full Text] [Related]  

  • 6. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA-SMILR modulates RhoA/ROCK signaling by targeting miR-141 to regulate vascular remodeling in pulmonary arterial hypertension.
    Lei S; Peng F; Li ML; Duan WB; Peng CQ; Wu SJ
    Am J Physiol Heart Circ Physiol; 2020 Aug; 319(2):H377-H391. PubMed ID: 32559140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
    Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
    Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
    [No Abstract]   [Full Text] [Related]  

  • 10. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
    Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
    J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
    Grobs Y; Awada C; Lemay SE; Romanet C; Bourgeois A; Toro V; Nadeau V; Shimauchi K; Orcholski M; Breuils-Bonnet S; Tremblay E; Provencher S; Paulin R; Boucherat O; Bonnet S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.
    Xing Y; Zhao S; Wei Q; Gong S; Zhao X; Zhou F; Ai-Lamki R; Ortmann D; Du M; Pedersen R; Shang G; Si S; Morrell NW; Yang J
    Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29449428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
    J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell Imaging Maps Inflammatory Cell Subsets to Pulmonary Arterial Hypertension Vasculopathy.
    Ferrian S; Cao A; McCaffrey EF; Saito T; Greenwald NF; Nicolls MR; Bruce T; Zamanian RT; Del Rosario P; Rabinovitch M; Angelo M
    Am J Respir Crit Care Med; 2024 Jan; 209(2):206-218. PubMed ID: 37934691
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
    Kato F; Sakao S; Takeuchi T; Suzuki T; Nishimura R; Yasuda T; Tanabe N; Tatsumi K
    Am J Physiol Lung Cell Mol Physiol; 2017 Nov; 313(5):L899-L915. PubMed ID: 28798259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension.
    Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H
    Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
    J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
    Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
    Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension.
    Ivy DD; McMurtry IF; Colvin K; Imamura M; Oka M; Lee DS; Gebb S; Jones PL
    Circulation; 2005 Jun; 111(22):2988-96. PubMed ID: 15927975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bmpr2 Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension.
    Hautefort A; Mendes-Ferreira P; Sabourin J; Manaud G; Bertero T; Rucker-Martin C; Riou M; Adão R; Manoury B; Lambert M; Boet A; Lecerf F; Domergue V; Brás-Silva C; Gomez AM; Montani D; Girerd B; Humbert M; Antigny F; Perros F
    Circulation; 2019 Feb; 139(7):932-948. PubMed ID: 30586714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.